Sunshine Biopharma Inc.
No SEC Form 4 filings for $SBFM in the last 30 days.
See all $SBFM insider activity →Sunshine Biopharma Inc. (SBFM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 On Thursday, October 08, 2026 at 8:00 AM ET Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering FORT LAUDERDALE, FL / ACCESS Newswire / October 8, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializin
Sunshine Biopharma (NASDAQ: SBFM) priced a $6M public offering at $0.55 per unit, including 10.9M units with two Series D warrants each. Proceeds will support working capital. The offering, expected to close by October 9, 2026, may dilute shares. SBFM markets 61 generic drugs in Canada and develops K1.1 mRNA for liver cancer and a SARS coronavirus inhibitor.
Sunshine Biopharma (SBFM) launched generic Ondansetron tablets in Canada, expanding its oncology support portfolio. The drug, equivalent to Zofran, treats nausea and vomiting from cancer treatments. The company has 61 generic drugs in Canada and plans 11 more launches in 2026. SBFM stock is down 10% at $0.79.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning SBFM (Sunshine Biopharma Inc.). Coverage has skewed bearish: 0 bullish, 3 neutral, and 6 bearish.
Recent SBFM coverage spans corporate actions, technology and financial news.
The small capital raise may cause modest dilution and slight downward pressure on the stock.
The financing adds cash but creates dilution pressure from warrants, likely weighing on the stock.
The new product may boost sales and improve market perception, potentially supporting the stock after a recent 10% decline.
Reverse split could reduce float and increase share price per share, affecting liquidity and short‑interest dynamics.
Positive clinical progress may boost investor confidence and drive the stock higher.
AlphAI scores every news story that mentions SBFM with an AI model for sentiment and relevance, and aggregates insider trades from Sunshine Biopharma Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Sunshine Biopharma Inc. (SBFM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 On Thursday, October 08, 2026 at 8:00 AM ET Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering FORT LAUDERDALE, FL / ACCESS Newswire / October 8, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializin
1 min readSunshine Biopharma (NASDAQ: SBFM) priced a $6M public offering at $0.55 per unit, including 10.9M units with two Series D warrants each. Proceeds will support working capital. The offering, expected to close by October 9, 2026, may dilute shares. SBFM markets 61 generic drugs in Canada and develops K1.1 mRNA for liver cancer and a SARS coronavirus inhibitor.
2 min readSunshine Biopharma (SBFM) launched generic Ondansetron tablets in Canada, expanding its oncology support portfolio. The drug, equivalent to Zofran, treats nausea and vomiting from cancer treatments. The company has 61 generic drugs in Canada and plans 11 more launches in 2026. SBFM stock is down 10% at $0.79.
2 min readSunshine Biopharma Inc. (SBFM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On September 15, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc. (the “Company”), approved by written consent authorizing the Company’s boar
1 min readSunshine Biopharma Inc. (NASDAQ: SBFM) announced its lead coronavirus drug candidate has entered IND-enabling studies. The company reported nanomolar potency against viral protease, broad-spectrum activity against SARS-CoV-2 variants, and strong oral bioavailability in multiple species. The drug also showed dose-dependent suppression of pulmonary viral replication in vivo. According to the company, the candidate is preferentially enriched in the lungs of mice and rats.
2 min readSunshine Biopharma (SBFM) advanced its lead coronavirus drug candidate into IND-enabling studies. The PLpro inhibitor showed nanomolar potency, broad in vitro activity against SARS-CoV-2 variants, and dose-dependent viral suppression in infected mice. The company reports high oral bioavailability and lung enrichment in multiple species. Sunshine Biopharma positions this as a differentiated antiviral program with scientific and commercial potential.
2 min readSunshine Biopharma (SBFM) reduced its Series B Warrant exercise price to $1.2046 due to recent common stock sales under an at-the-market offering. The adjustment reflects dilution mechanics and may impact investors holding these warrants. TipRanks' AI Analyst rates SBFM as Neutral, citing weak financials and bearish technicals.
1 min readSunshine Biopharma (SBFM) filed a registration statement for 25.5M shares of common stock issuable upon exercise of Series B Warrants, potentially raising $31.1M. The warrants have an exercise price of $1.2202 and expire in 2029. SBFM's stock last traded at $1.27 per share.
1 min readDr. Andrew Keller will not seek reelection to Sunshine Biopharma's board when his term ends at the next annual meeting. The company filed this update in an SEC 8-K form.
1 min readSunshine Biopharma Inc. (SBFM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 25, 2026, Dr. Andrew Keller, a director of Sunshine Biopharma Inc. (the “Company”), notified the Company that he
1 min read
